Table 2.
Correlation between ITLN-1 and clinicopathological variables of HCC.
| Variables | Patients, n | ITLN-1 expression | X2 | P | |
|---|---|---|---|---|---|
| Low, n (%) | High, n (%) | ||||
| Age (years) | 0.806 | .369 | |||
| ≤45 | 71 | 58 (49.6%) | 13 (40.6%) | ||
| >45 | 78 | 59 (50.4%) | 19 (59.4%) | ||
| Gender | 0.75 | .387 | |||
| Male | 128 | 99 (84.6%) | 29 (90.6%) | ||
| Female | 21 | 18 (15.4%) | 3 (9.4%) | ||
| AFP | 0.097 | .755 | |||
| Positive | 50 | 10 (31.3%) | 40 (34.2%) | ||
| Negative | 99 | 22 (68.7%) | 77 (65.8%) | ||
| Tumor status | 3.64 | .056 | |||
| T1/T2 | 95 | 70 (59.8%) | 25 (78.1%) | ||
| T3/T4 | 54 | 47 (40.2%) | 7 (21.9%) | ||
| Tumor size (cm) | 6.665 | .010 | |||
| < 5 | 59 | 40 (34.2%) | 19 (59.4%) | ||
| ≥ 5 | 90 | 77 (65.8%) | 13 (40.6%) | ||
| Tumor differentiation | 6.112 | .013 | |||
| I | 25 | 15 (12.8%) | 10 (31.3%) | ||
| II–III | 124 | 102 (87.2%) | 22 (68.7%) | ||
| BCLC stage | 0.194 | .66 | |||
| 0-A | 51 | 39 (33.3%) | 12 (37.5%) | ||
| B-C | 98 | 78 (66.7%) | 20 (62.5%) | ||
| Vascular invasion | 37.385 | <.001 | |||
| Positive | 33 | 26 (51.0%) | 7 (7.2%) | ||
| Negative | 116 | 25 (49.0%) | 91 (92.8%) | ||
| Tumor nodules | 2.028 | .154 | |||
| Single | 106 | 80 (68.4%) | 26 (81.3%) | ||
| Multiple | 43 | 37 (31.6%) | 6 (18.7%) | ||
| HBV | 0.096 | .757 | |||
| Positive | 137 | 108 (92.3%) | 29 (90.6%) | ||
| Negative | 12 | 9 (7.7%) | 3 (9.4%) | ||
| HBV copies | 1.899 | .168 | |||
| Positive | 99 | 81 (69.2%) | 18 (56.3%) | ||
| Negative | 50 | 36 (30.8%) | 14 (43.7%) | ||
| Capsule | 50.495 | <.001 | |||
| Incomplete | 57 | 49 (67.1%) | 8 (10.5%) | ||
| Complete | 92 | 24 (32.9%) | 68 (89.5%) | ||
| Recurrence | 41.582 | <.001 | |||
| No | 47 | 12 (12.8%) | 35 (63.6%) | ||
| Yes | 102 | 82 (87.2%) | 20 (36.4%) | ||
| Cirrhosis | 46.104 | <.001 | |||
| I | 63 | 19 (20.7%) | 44 (77.2%) | ||
| II–III | 86 | 73 (79.3%) | 13 (22.8%) | ||
AFP = alpha-fetoprotein; BCLC = Barcelona Clinic Liver Cancer; ITLN-1 = intelectin-1.